Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lucia Masarova

Showing results (1-10 of 112) with videos related to

Pageof 12
Sort By:
Clinical Advances in Hematology & Oncology : H&O|June 13, 2019
The evolving understanding of prognosis in post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis vs primary myelofibrosisLucia Masarova, Srdan Verstovsek
Expert Opinion on Emerging Drugs|May 4, 2019
Emerging drugs for essential thrombocythemiaLucia Masarova, Srdan Verstovsek
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2018
Therapeutic Approach to Young Patients With Low-Risk Essential Thrombocythemia: Primum Non NocereLucia Masarova, Srdan Verstovsek
Clinical Lymphoma, Myeloma & Leukemia|December 22, 2023
SOHO State of the Art Update and Next Questions: Novel Therapies for Polycythemia VeraLucia Masarova, Helen T Chifotides
Blood|October 2, 2024
How I individualize selection of JAK inhibitors for patients with myelofibrosisLucia Masarova, Helen T Chifotides
Cancers|October 14, 2020
Novel Concepts of Treatment for Patients with Myelofibrosis and Related NeoplasmsPrithviraj Bose, Lucia Masarova, Srdan Verstovsek
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|October 11, 2019
Novel treatment strategies for myeloproliferative neoplasmsPrithviraj Bose, Lucia Masarova, Srdan Verstovsek
Clinical Advances in Hematology & Oncology : H&O|February 13, 2023
A review of essential thrombocythemia and its complicationsRodrick Babakhanlou, Lucia Masarova, Srdan Verstovsek
Current Hematologic Malignancy Reports|June 23, 2019
The Rationale for Immunotherapy in Myeloproliferative NeoplasmsLucia Masarova, Prithviraj Bose, Srdan Verstovsek
Clinical Lymphoma, Myeloma & Leukemia|February 16, 2023
SOHO State of the Art Updates and Next Questions: Novel Therapeutic Strategies in Development for MyelofibrosisHelen T Chifotides, Lucia Masarova, Srdan Verstovsek
Pageof 12

Showing results (1-10 of 112) with videos related to

Sort By:
Pageof 12
Clinical Advances in Hematology & Oncology : H&O|June 13, 2019
The evolving understanding of prognosis in post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis vs primary myelofibrosisLucia Masarova, Srdan Verstovsek
Expert Opinion on Emerging Drugs|May 4, 2019
Emerging drugs for essential thrombocythemiaLucia Masarova, Srdan Verstovsek
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2018
Therapeutic Approach to Young Patients With Low-Risk Essential Thrombocythemia: Primum Non NocereLucia Masarova, Srdan Verstovsek
Clinical Lymphoma, Myeloma & Leukemia|December 22, 2023
SOHO State of the Art Update and Next Questions: Novel Therapies for Polycythemia VeraLucia Masarova, Helen T Chifotides
Blood|October 2, 2024
How I individualize selection of JAK inhibitors for patients with myelofibrosisLucia Masarova, Helen T Chifotides
Cancers|October 14, 2020
Novel Concepts of Treatment for Patients with Myelofibrosis and Related NeoplasmsPrithviraj Bose, Lucia Masarova, Srdan Verstovsek
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|October 11, 2019
Novel treatment strategies for myeloproliferative neoplasmsPrithviraj Bose, Lucia Masarova, Srdan Verstovsek
Clinical Advances in Hematology & Oncology : H&O|February 13, 2023
A review of essential thrombocythemia and its complicationsRodrick Babakhanlou, Lucia Masarova, Srdan Verstovsek
Current Hematologic Malignancy Reports|June 23, 2019
The Rationale for Immunotherapy in Myeloproliferative NeoplasmsLucia Masarova, Prithviraj Bose, Srdan Verstovsek
Clinical Lymphoma, Myeloma & Leukemia|February 16, 2023
SOHO State of the Art Updates and Next Questions: Novel Therapeutic Strategies in Development for MyelofibrosisHelen T Chifotides, Lucia Masarova, Srdan Verstovsek
Pageof 12